微创机器人-B今日盘中大幅上涨5.24%，引起了市场的广泛关注。
消息面上，多重利好因素共同推动了股价的上涨。瑞银近日将微创机器人-B的评级由“中性”上调至“买入”，并将目标价大幅上调至35.9港元，预计公司未来三年收入及盈利将实现高速增长。同时，公司自主研发的鸿鹄骨科手术机器人成功获得欧洲CE认证，成为国内首款获此认证的关节置换手术机器人，标志着其产品国际化取得重要突破。
此外，北京、湖南等地相继出台手术机器人入院及收费标准政策，为整个行业带来了积极信号。公司自身也设定了积极的发展目标，计划今年总收入实现同比翻倍，并将海外收入占比提升至80%以上，有望在上半年实现收支平衡，这些因素共同增强了投资者对公司未来发展的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.